Hetiamacin E and F, New Amicoumacin Antibiotics from Bacillus subtilis PJS Using MS/MS-Based Molecular Networking.
Ting WangQinpei LuCheng-Hang SunDmitrii LukianovIlya Andreevich OstermanPetr Vladimirovich SergievOlga Anatolievna DontsovaXinxin HuXuefu YouShaowei LiuGang WuPublished in: Molecules (Basel, Switzerland) (2020)
To combat escalating levels of antibiotic resistance, novel strategies are developed to address the everlasting demand for new antibiotics. This study aimed at investigating amicoumacin antibiotics from the desert-derived Bacillus subtilis PJS by using the modern MS/MS-based molecular networking approach. Two new amicoumacins, namely hetiamacin E (1) and hetiamacin F (2), were finally isolated. The planar structures were determined by analysis of extensive NMR spectroscopic and HR-ESI-MS data, and the absolute configurations were concluded by analysis of the CD spectrum. Hetiamacin E (1) showed strong antibacterial activities against methicillin-sensitive and resistant Staphylococcus epidermidis at 2-4 µg/mL, and methicillin-sensitive and resistant Staphylococcus aureus at 8-16 µg/mL. Hetiamacin F (2) exhibited moderate antibacterial activities against Staphylococcus sp. at 32 µg/mL. Both compounds were inhibitors of protein biosynthesis demonstrated by a double fluorescent protein reporter system.
Keyphrases
- staphylococcus aureus
- bacillus subtilis
- ms ms
- biofilm formation
- methicillin resistant staphylococcus aureus
- liquid chromatography tandem mass spectrometry
- high resolution
- protein protein
- silver nanoparticles
- molecular docking
- amino acid
- electronic health record
- single molecule
- crispr cas
- quantum dots
- living cells
- ultra high performance liquid chromatography
- high performance liquid chromatography
- anti inflammatory
- big data
- candida albicans
- essential oil
- solid state
- escherichia coli
- artificial intelligence
- cell wall
- fluorescent probe
- nk cells
- solid phase extraction
- molecular dynamics simulations